
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

agilon health, inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-40332

(Commission File Number)

37-1915147

(IRS Employer
Identification No.)

440 Polaris Parkway, Suite 550

Westerville, Ohio

(Address of Principal Executive Offices)

43082

(Zip Code)

Registrant's Telephone Number, Including Area Code: 562 256-3800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.01 per share	AGL	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2026, agilon health, inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). Below are the final voting results.

Proposal No. 1 - Election of Directors

The following three individuals were elected to the Company's Board of Directors to serve as Class II directors until the Company's 2029 annual meeting of stockholders and until their successors have been duly elected and qualified.

Name	Votes For	Votes Against	Votes Abstained	Broker Non-Votes
Diana McKenzie	11,679,958	177,760	7,034	1,870,677
Karen McLoughlin	9,525,491	2,332,208	7,053	1,870,677
Ronald Williams	10,837,623	1,019,347	7,782	1,870,677

Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Votes For	Votes Against	Votes Abstained
13,712,368	6,616	16,445

Proposal No. 3 - Non-Binding Vote on Executive Compensation

The stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers.

Votes For	Votes Against	Votes Abstained	Broker Non-Votes
11,228,258	627,870	8,624	1,870,677

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

agilon health, inc.

Date: June 3, 2026

By: /s/ JEFFREY SCHWANEKE

Jeffrey Schwaneke
Chief Financial Officer